Search results
Results from the WOW.Com Content Network
The Global Health Innovative Technology Fund (GHIT Fund), headquartered in Japan, is an international public-private partnership between the Government of Japan (Ministry of Foreign Affairs and Ministry of Health, Labour and Welfare), 16 pharmaceutical and diagnostics companies (Astellas, Chugai, Eisai, Daiichi Sankyo, Fujifilm, GlaxoSmithKline, Johnson & Johnson, Kyowa Hakko Kirin, Merck ...
Global X in November 2023 also launched an ETF option for volatile emerging markets. [6] Global X filed its application to become one of the first companies to offer a Spot Bitcoin ETF in the US on August 23, 2023. [7] In its first year of operation, the Global X Blockchain ETF dropped 76.7 percent, dropping from a peak of $125 of assets. [8]
Global X Investments Canada Inc. (formerly Horizons ETFs) is a financial services company that offers exchange-traded funds. On May 1, 2024, the company changed its name from Horizons ETFs to Global X Investments Canada Inc. [2] In April 2017, Global X began offering the first cannabis industry focused exchange-traded fund (ETF), Global X Marijuana Life Sciences Index ETF.
In March 2019, Deerfield announced a strategic partnership with Harvard University to fund the development of drugs and medical treatments. Deerfield would commit $100 million to it which would be funded through a new company, Lab1636. [3] [6]
TSX: HMU – the Horizons BetaPro S&P/TSX Global Mining Bull Plus ETF tracks two times (200%) the daily performance of the S&P/TSX Global Mining Index. TSX: HMD – the Horizons BetaPro S&P/TSX Global Mining Bear Plus ETF tracks two times (200%) inverse the daily performance of the S&P/TSX Global Mining Index.
Novo Holdings A/S (formerly Novo A/S) [1] is the Novo Nordisk Foundation's wholly owned holding company for Novo Nordisk A/S and Novozymes A/S.Novo Holdings A/S was established in 1999 and manages the Novo Nordisk Foundation's assets, which in 2023 was worth almost DKK 1,114 billion [2] [3] [4] Danish Kroner (approximately US$163 billion).
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Drugs or medicines may be withdrawn from commercial markets because of risks to patients, but also because of commercial reasons (e.g. lack of demand and relatively high production costs).